Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy

Autores
Zorzopulos, Jorge; Opal, Steven M.; Hernando Insúa, Andrés; Rodriguez, Juan M.; Elías, Fernanda; Fló, Juan; López, Ricardo A.; Chasseing, Norma Alejandra; Lux, Victoria Adela R.; Coronel, Maria Florencia; Franco, Raul; Montaner, Alejandro D; Horn, David L
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The immune responses of humans and animals to insults (i.e., infections, traumas, tumoral transformation and radiation) are based on an intricate network of cells and chemical messengers. Abnormally high inflammation immediately after insult or abnormally prolonged pro-inflammatory stimuli bringing about chronic inflammation can lead to life-threatening or severely debilitating diseases. Mesenchymal stem cell (MSC) transplant has proved to be an effective therapy in preclinical studies which evaluated a vast diversity of inflammatory conditions. MSCs lead to resolution of inflammation, preparation for regeneration and actual regeneration, and then ultimate return to normal baseline or homeostasis. However, in clinical trials of transplanted MSCs, the expectations of great medical benefit have not yet been fulfilled. As a practical alternative to MSC transplant, a synthetic drug with the capacity to boost endogenous MSC expansion and/or activation may also be effective. Regarding this, IMT504, the prototype of a major class of immunomodulatory oligonucleotides, induces in vivo expansion of MSCs, resulting in a marked improvement in preclinical models of neuropathic pain, osteoporosis, diabetes and sepsis. IMT504 is easily manufactured and has an excellent preclinical safety record. In the small number of patients studied thus far, IMT504 has been well-tolerated, even at very high dosage. Further clinical investigation is necessary to demonstrate the utility of IMT504 for resolution of inflammation and regeneration in a broad array of human diseases that would likely benefit from an immunoprotective/immunoregenerative therapy.
Fil: Zorzopulos, Jorge. Immunotech; Argentina
Fil: Opal, Steven M.. Memorial Hospital of Rhode Island; Estados Unidos. Alpert Medical School; Estados Unidos
Fil: Hernando Insúa, Andrés. Fundación Pablo Cassara; Argentina
Fil: Rodriguez, Juan M.. Fundación Pablo Cassara; Argentina
Fil: Elías, Fernanda. Fundación Pablo Cassara; Argentina
Fil: Fló, Juan. Immunotech; Argentina
Fil: López, Ricardo A.. Imunotech; Argentina
Fil: Chasseing, Norma Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Lux, Victoria Adela R.. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Coronel, Maria Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Franco, Raul. Imunotech; Argentina
Fil: Montaner, Alejandro D. Fundación Pablo Cassara; Argentina
Fil: Horn, David L. David Horn Llc; Estados Unidos
Materia
Imt504
Mesenchymal Stem Cells
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/24562
Acceder
id CONICETDig_037ec4d22d61dd240a3fcefda283e143
oai_identifier_str oai:ri.conicet.gov.ar:11336/24562
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapyZorzopulos, JorgeOpal, Steven M.Hernando Insúa, AndrésRodriguez, Juan M.Elías, FernandaFló, JuanLópez, Ricardo A.Chasseing, Norma AlejandraLux, Victoria Adela R.Coronel, Maria FlorenciaFranco, RaulMontaner, Alejandro DHorn, David LImt504Mesenchymal Stem Cellshttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The immune responses of humans and animals to insults (i.e., infections, traumas, tumoral transformation and radiation) are based on an intricate network of cells and chemical messengers. Abnormally high inflammation immediately after insult or abnormally prolonged pro-inflammatory stimuli bringing about chronic inflammation can lead to life-threatening or severely debilitating diseases. Mesenchymal stem cell (MSC) transplant has proved to be an effective therapy in preclinical studies which evaluated a vast diversity of inflammatory conditions. MSCs lead to resolution of inflammation, preparation for regeneration and actual regeneration, and then ultimate return to normal baseline or homeostasis. However, in clinical trials of transplanted MSCs, the expectations of great medical benefit have not yet been fulfilled. As a practical alternative to MSC transplant, a synthetic drug with the capacity to boost endogenous MSC expansion and/or activation may also be effective. Regarding this, IMT504, the prototype of a major class of immunomodulatory oligonucleotides, induces in vivo expansion of MSCs, resulting in a marked improvement in preclinical models of neuropathic pain, osteoporosis, diabetes and sepsis. IMT504 is easily manufactured and has an excellent preclinical safety record. In the small number of patients studied thus far, IMT504 has been well-tolerated, even at very high dosage. Further clinical investigation is necessary to demonstrate the utility of IMT504 for resolution of inflammation and regeneration in a broad array of human diseases that would likely benefit from an immunoprotective/immunoregenerative therapy.Fil: Zorzopulos, Jorge. Immunotech; ArgentinaFil: Opal, Steven M.. Memorial Hospital of Rhode Island; Estados Unidos. Alpert Medical School; Estados UnidosFil: Hernando Insúa, Andrés. Fundación Pablo Cassara; ArgentinaFil: Rodriguez, Juan M.. Fundación Pablo Cassara; ArgentinaFil: Elías, Fernanda. Fundación Pablo Cassara; ArgentinaFil: Fló, Juan. Immunotech; ArgentinaFil: López, Ricardo A.. Imunotech; ArgentinaFil: Chasseing, Norma Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Lux, Victoria Adela R.. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Coronel, Maria Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Franco, Raul. Imunotech; ArgentinaFil: Montaner, Alejandro D. Fundación Pablo Cassara; ArgentinaFil: Horn, David L. David Horn Llc; Estados UnidosBaishideng Publishing Group Inc2017-03-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/24562Zorzopulos, Jorge; Opal, Steven M.; Hernando Insúa, Andrés; Rodriguez, Juan M.; Elías, Fernanda; et al.; Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy; Baishideng Publishing Group Inc; World Journal of Stem Cells; 9; 3; 26-3-2017; 45-671948-02101948-0210CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.wjgnet.com/1948-0210/full/v9/i3/45.htminfo:eu-repo/semantics/altIdentifier/doi/ 10.4252/wjsc.v9.i3.45info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368622/info:eu-repo/semantics/altIdentifier/pmid/28396715info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:00:27Zoai:ri.conicet.gov.ar:11336/24562instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:00:28.207CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
title Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
spellingShingle Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
Zorzopulos, Jorge
Imt504
Mesenchymal Stem Cells
title_short Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
title_full Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
title_fullStr Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
title_full_unstemmed Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
title_sort Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
dc.creator.none.fl_str_mv Zorzopulos, Jorge
Opal, Steven M.
Hernando Insúa, Andrés
Rodriguez, Juan M.
Elías, Fernanda
Fló, Juan
López, Ricardo A.
Chasseing, Norma Alejandra
Lux, Victoria Adela R.
Coronel, Maria Florencia
Franco, Raul
Montaner, Alejandro D
Horn, David L
author Zorzopulos, Jorge
author_facet Zorzopulos, Jorge
Opal, Steven M.
Hernando Insúa, Andrés
Rodriguez, Juan M.
Elías, Fernanda
Fló, Juan
López, Ricardo A.
Chasseing, Norma Alejandra
Lux, Victoria Adela R.
Coronel, Maria Florencia
Franco, Raul
Montaner, Alejandro D
Horn, David L
author_role author
author2 Opal, Steven M.
Hernando Insúa, Andrés
Rodriguez, Juan M.
Elías, Fernanda
Fló, Juan
López, Ricardo A.
Chasseing, Norma Alejandra
Lux, Victoria Adela R.
Coronel, Maria Florencia
Franco, Raul
Montaner, Alejandro D
Horn, David L
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Imt504
Mesenchymal Stem Cells
topic Imt504
Mesenchymal Stem Cells
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The immune responses of humans and animals to insults (i.e., infections, traumas, tumoral transformation and radiation) are based on an intricate network of cells and chemical messengers. Abnormally high inflammation immediately after insult or abnormally prolonged pro-inflammatory stimuli bringing about chronic inflammation can lead to life-threatening or severely debilitating diseases. Mesenchymal stem cell (MSC) transplant has proved to be an effective therapy in preclinical studies which evaluated a vast diversity of inflammatory conditions. MSCs lead to resolution of inflammation, preparation for regeneration and actual regeneration, and then ultimate return to normal baseline or homeostasis. However, in clinical trials of transplanted MSCs, the expectations of great medical benefit have not yet been fulfilled. As a practical alternative to MSC transplant, a synthetic drug with the capacity to boost endogenous MSC expansion and/or activation may also be effective. Regarding this, IMT504, the prototype of a major class of immunomodulatory oligonucleotides, induces in vivo expansion of MSCs, resulting in a marked improvement in preclinical models of neuropathic pain, osteoporosis, diabetes and sepsis. IMT504 is easily manufactured and has an excellent preclinical safety record. In the small number of patients studied thus far, IMT504 has been well-tolerated, even at very high dosage. Further clinical investigation is necessary to demonstrate the utility of IMT504 for resolution of inflammation and regeneration in a broad array of human diseases that would likely benefit from an immunoprotective/immunoregenerative therapy.
Fil: Zorzopulos, Jorge. Immunotech; Argentina
Fil: Opal, Steven M.. Memorial Hospital of Rhode Island; Estados Unidos. Alpert Medical School; Estados Unidos
Fil: Hernando Insúa, Andrés. Fundación Pablo Cassara; Argentina
Fil: Rodriguez, Juan M.. Fundación Pablo Cassara; Argentina
Fil: Elías, Fernanda. Fundación Pablo Cassara; Argentina
Fil: Fló, Juan. Immunotech; Argentina
Fil: López, Ricardo A.. Imunotech; Argentina
Fil: Chasseing, Norma Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Lux, Victoria Adela R.. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Coronel, Maria Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Franco, Raul. Imunotech; Argentina
Fil: Montaner, Alejandro D. Fundación Pablo Cassara; Argentina
Fil: Horn, David L. David Horn Llc; Estados Unidos
description The immune responses of humans and animals to insults (i.e., infections, traumas, tumoral transformation and radiation) are based on an intricate network of cells and chemical messengers. Abnormally high inflammation immediately after insult or abnormally prolonged pro-inflammatory stimuli bringing about chronic inflammation can lead to life-threatening or severely debilitating diseases. Mesenchymal stem cell (MSC) transplant has proved to be an effective therapy in preclinical studies which evaluated a vast diversity of inflammatory conditions. MSCs lead to resolution of inflammation, preparation for regeneration and actual regeneration, and then ultimate return to normal baseline or homeostasis. However, in clinical trials of transplanted MSCs, the expectations of great medical benefit have not yet been fulfilled. As a practical alternative to MSC transplant, a synthetic drug with the capacity to boost endogenous MSC expansion and/or activation may also be effective. Regarding this, IMT504, the prototype of a major class of immunomodulatory oligonucleotides, induces in vivo expansion of MSCs, resulting in a marked improvement in preclinical models of neuropathic pain, osteoporosis, diabetes and sepsis. IMT504 is easily manufactured and has an excellent preclinical safety record. In the small number of patients studied thus far, IMT504 has been well-tolerated, even at very high dosage. Further clinical investigation is necessary to demonstrate the utility of IMT504 for resolution of inflammation and regeneration in a broad array of human diseases that would likely benefit from an immunoprotective/immunoregenerative therapy.
publishDate 2017
dc.date.none.fl_str_mv 2017-03-26
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/24562
Zorzopulos, Jorge; Opal, Steven M.; Hernando Insúa, Andrés; Rodriguez, Juan M.; Elías, Fernanda; et al.; Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy; Baishideng Publishing Group Inc; World Journal of Stem Cells; 9; 3; 26-3-2017; 45-67
1948-0210
1948-0210
CONICET Digital
CONICET
url http://hdl.handle.net/11336/24562
identifier_str_mv Zorzopulos, Jorge; Opal, Steven M.; Hernando Insúa, Andrés; Rodriguez, Juan M.; Elías, Fernanda; et al.; Immunomodulatory oligonucleotide IMT504: effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy; Baishideng Publishing Group Inc; World Journal of Stem Cells; 9; 3; 26-3-2017; 45-67
1948-0210
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.wjgnet.com/1948-0210/full/v9/i3/45.htm
info:eu-repo/semantics/altIdentifier/doi/ 10.4252/wjsc.v9.i3.45
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368622/
info:eu-repo/semantics/altIdentifier/pmid/28396715
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Baishideng Publishing Group Inc
publisher.none.fl_str_mv Baishideng Publishing Group Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269639859503104
score 13.13397

Publicaciones similares